The use of GnRH analogues in early and advanced breast carcinomas;Analogues de la LHRH: Leur utilisation dans le traitement du cancer du sein en situation métastatique et adjuvante

Gynecologie Obstetrique et Fertilite

Volumn 33, Issue 11, 2005, Pages 914-919

  Segura C ^a   Avenin, D ^a   Gligorov, J ^a   Selle, F ^a   Esteso A ^a   Beerblock, K ^a   Emile, G ^a   Do Huyen, N ^a   Lotz, J P ^a  

^a HÔPITAL TENON   (France)

Author keywords

Breast carcinomas; Estrogens; LHRH analogues; Ovarian ablation

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY; COMPARATIVE STUDY; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HUMAN; IRRADIATION; METASTASIS; OUTCOMES RESEARCH; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; QUALITY OF LIFE; SURVIVAL TIME; TOXICITY;

EID: 28244442768     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2005.09.010     Document Type: Article

References (21)

1. G.W. Beatson On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases Lancet 2 1896 104 107 (162-5)
2. Early Breast Cancer Trialists' Collaborative group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Lancet 365 2005 1687 1717
3. R.W. Blamey, W. Jonat, M. Kaufmann, A.R. Bianco, and M. Namer Goserelin depot in the treatment of premenopausal advanced breast cancer Eur. J. Cancer 28A 4-5 1992 810 814
4. A.R. Bianco, R. Rosso, F. Calabresi, M. Fiorentino, M. Lopez, and P.G. Sismondi LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study) Eur. J. Gynaecol. Oncol. 12 6 1991 429 437
5. C.W. Taylor, S. Green, W.S. Dalton, S. Martino, D. Rector, and J.N. Ingle Multicenter randomized clinical trial of goserelin vs. surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An Intergroup Study J. Clin. Oncol. 16 3 1998 994 999
6. M. Crump, C.A. Sawka, G. DeBoer, R.B. Buchanan, J.N. Ingle, and J. Forbes An individual patient-based meta-analysis of tamoxifen vs. ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer Breast Cancer Res. Treat. 44 3 1997 201 210
7. W. Jonat, M. Kaufmann, R.W. Blamey, A. Howell, J.P. Collins, and A. Coates A randomised study to compare the effect of the luteinizing hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer Eur. J. Cancer 31A 2 1995 137 142
8. J.G. Klijn, R.W. Blamey, F. Boccardo, T. Tominaga, L. Duchateau, R. Sylvester Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist vs. LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials J. Clin. Oncol. 19 2001 343 353
9. J.G. Klijn, L.V. Beex, L. Mauriac, J.A. van Zijl, C. Veyret, and J. Wildiers Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study J. Natl. Cancer Inst. 92 11 2000 903 911
10. F. Boccardo, A. Rubagotti, A. Perrotta, D. Amoroso, M. Balestrero, and A. De Matteis Ovarian ablation vs. goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study Ann. Oncol. 4 1994 337 342
11. A. Howell, J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J.F. Forbes For the ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 9453 2005 60 62
12. P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, and M.J. Piccart A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N. Engl. J. Med. 349 19 2003 1793 1802
13. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, T. Delozier Intergroup Exemestane Study A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N. Engl. J. Med. 350 11 2004 1081 1092
14. R. Jakesz, H. Hausmaninger, E. Kubista, M. Gnant, C. Menzel, T. Bavernhofer Austrian Breast and Colorectal Cancer Study Group Trial 5 Randomized adjuvant trial of tamoxifen and goserelin vs. cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. Austrian Breast and Colorectal Cancer Study Group Trial 5 J. Clin. Oncol. 20 24 2002 4621 4627
15. C.W. Jonat, M. Kaufmann, W. Sauerbrei, R. Blamey, J. Cuzick, and M. Namer Goserelin vs. cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. The Zoladex Early Breast Cancer Research Association Study J. Clin. Oncol. 20 2002 4628 4635
16. M. Castiglione-Gertsch, A. O'Neill, K.N. Price, A. Goldhirsch, A.S. Coates, M. Colleoni International Breast Cancer Study Group Adjuvant chemotherapy followed by goserelin vs. either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial J. Natl. Cancer Inst. 17 95 2003 1833 1846 (24)
17. R. Arriagada, M.G. Le, M. Spielmann, L. Mauriac, J. Bonneterre, and M. Namer Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy Ann. Oncol. 3 2005 389 396
18. M. Vanhuyse, C. Fournier, and J. Bonneterre Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients Ann. Oncol. 16 2005 1283 1288
19. Gnant M, Jakesz R, Mlineritsh B, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserilin plus anastrazole vs. goserelin plus tamoxifen. Bone density subprotocol results of a randomized multicenter trial (ABSCG-12). Proc SABCS 2004, abstr 6.
20. D. Meirow, G. Assad, J. Dor, and J. Rabinivici The LH-RH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice Hum. Reprod. 6 2004 1294 1299
21. S.-P. De Vence Recommandations pour la pratique clinique «:cancer du sein:» Oncologie 7 2005 342 379